SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community chatter focused on potential S&P 500 inclusion and the impact of future interest rate cuts. Bullish sentiment is high, with some expecting a significant price increase following earnings, while others are wary of a potential sell-off. The community is actively discussing potential earnings leaks and institutional buying patterns.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital ($GLXY) is trending due to a recently announced $1 billion convertible note offering, leading to community debate about potential dilution and the company's growth strategy. Some investors view the offering as a strategic move to fund data center expansion and capitalize on AI opportunities, while others express concern over the impact on existing shareholders. Community members are actively discussing the implications of the offering, potential ERCOT approval, and comparing GLXY to other stocks in the crypto and AI sectors.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZ is trending as community members discuss the company's recent decision to enact a reverse stock split. Some investors view this as a strategic move to attract institutional investors and increase the stock price, while others worry about potential dilution and question the company's management. Discussions also involve ETHZ's relationship to Ethereum's price movements and comparisons to other crypto-related stocks.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors anticipate the upcoming earnings report, focusing on potential margin improvements and guidance for 2026. Community discussions revolve around the impact of rising costs, government regulations, and Optum's performance, while some traders are closely monitoring technical indicators and analyst ratings.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors debate its future ahead of upcoming earnings, with key concerns including potential dividend cuts, restructuring impacts, and the influence of Amazon. Community discussions revolve around whether UPS can maintain current levels or if a further decline is imminent. Sentiment is mixed, with some anticipating a significant move post-earnings while others point to the stock's long-term value and high dividend yield.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending following Rosenblatt's bullish report highlighting a major AI data center deal, positioning the company to challenge competitors in the AI infrastructure space. Community members are debating the significance of this move, with some questioning the hype and others pointing to Qualcomm's attractive valuation compared to peers. Option volume is elevated, suggesting increased investor interest.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies ($AVR) is trending as the company enrolls its first patients in the global PARADIGM pivotal trial of its DurAVR transcatheter heart valve. Despite the positive catalyst, the community is discussing the stock's recent price action and cash runway, with some speculating about future potential and others expressing concern over dilution.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLA is trending due to a significant stock drop following a paused trial of its gene therapy nex-z after a patient experienced liver issues, sparking discussions around the severity and implications for the company's pipeline. The community is debating whether this is an overreaction and a buying opportunity, or a sign of deeper problems with the therapy, while analysts are adjusting price targets but largely maintaining buy ratings. Some traders anticipate a potential short squeeze given the high short interest and the company's cash reserves.

Rambus, Inc. engages in the provision of cutting-edge semiconductor and Internet Protocol products, spanning memory and interfaces to security, smart sensors and lighting. Its products include Memory Interface Chips, Interface IP, and Security IP. The company was founded by P. Michael Farmwald and Mark A. Horowitz in March 1990 and is headquartered in Sunnyvale, CA.

Rambus Inc.

Rambus is trending amid discussions about earnings and revenue, with community members pointing to the stock's valuation and margin performance. Despite positive momentum in DDR5 memory products and AI solutions, some traders express concerns about earnings quality. The stock's high valuation relative to earnings has sparked debate as it relates to the AI and memory technology sectors.

Pump.fun

$PUMP is gaining traction within the Solana meme coin ecosystem, particularly on Pump.fun, with the community rallying around a 'We're All Gonna Make It' ($WAGMI) mentality. Traders are closely watching for meme rotations and potential breakouts, emphasizing community support and long-term holding.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates

MiMedx (MDXG) delivered earnings and revenue surprises of +66.67% and +10.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MiMedx and Organogenesis stocks tumble after CMS proposal to slash spending

Investing.com -- MiMedx Group (NASDAQ:MDXG) stock fell 19% and Organogenesis Holdings (NASDAQ:ORGO) shares plunged 36% after the Centers for Medicare&Medicaid Services (CMS) proposed a rule that would drastically cut Medicare spending on skin substitutes.

Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

EX-MiMEDX EMPLOYEES ALLEGE MiMEDX "PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE PRODUCTS"

EX-MiMEDX EMPLOYEES ALLEGE MiMEDX 'PRESSURE[D] HEALTHCARE PROVIDERS TO TREAT WOUNDED VETERANS, DIABETICS, CHRONIC WOUND SUFFERERS, AND OTHER PATIENTS WITH MEDICALLY UNNECESSARY OR UNSUITABLE...

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES'

THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES' THIRD DEFENDANT FIGHTS BACK AGAINST MiMEDX, CLAIMING 'DISREPUTABLE AND UNLAWFUL BUSINESS PRACTICES...

DEFENDANT FIGHTS BACK AGAINST MiMEDX "BLATANT INTIMIDATION" NON-COMPETE SUIT

DEFENDANT FIGHTS BACK AGAINST MiMEDX 'BLATANT INTIMIDATION' NON-COMPETE SUIT DEFENDANT FIGHTS BACK AGAINST MiMEDX 'BLATANT INTIMIDATION' NON-COMPETE SUIT PR Newswire MARIETTA, Ga., Aug. 26, 2024...

Craig-Hallum Sticks to Its Buy Rating for MiMedx Group (MDXG)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on MiMedx Group (MDXG Research Report) today. The company's shares closed yester...

MIMEDX Provides Update on AXIOFILL  Request for Designation ( RFD ) from FDA

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the...

MiMedx Group (MDXG, $7.83) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 25, 2024

This is a Bearish indicator signaling MDXG's price could decline from here. Traders may explore shorting the stock or put options...

MiMedx Group (MDXG, $8.03) entered Downtrend as Momentum indicator drops below 0 level on Mar 22, 2024

This indicator may be signaling that MDXG's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Mimedx Group Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$6.73
Prev Close	$6.76
Open	$6.76
Dividend Yield	0.00%
50-Day Moving Average	$6.99
Beta	1.02
Avg. Volume	547,942.76
PE Ratio	31.34

52-Week High	$10.14
52-Week Low	$5.69
Market Capitalization	$1B
EPS (Annual)	$0.2846
Price to Book	4.62
Revenue Per Employee	$416,820.79
Enterprise Value/EBITDA	N/A

MDXG
Mimedx Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MDXG News

MDXGMimedx Group Inc